Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gland PharmaNSE:GLAND +0.09%81 3-Year EBITDA Growth Rate is 16.60% as of Jun. 2026, which is 69% above its 10-year median of 9.85. GuruFocus rates NSE:GLAND with a GF Score™ of 81/100 and a GF Value™ of ₹2,239.48 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 809 Drug Manufacturers companies, Gland Pharma ranks better than 63.41% on this metric.
During the past 12 months, Gland Pharma's average EBITDA Per Share Growth Rate was 28.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 2.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Gland Pharma was 36.50% per year. The lowest was -5.20% per year. And the median was 9.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Gland Pharma 3-Year EBITDA Growth Rate Related Terms
NSE:GLAND vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Gland Pharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.60% mean?
Gland Pharma (NSE:GLAND) has a 3-Year EBITDA Growth Rate of 16.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gland Pharma and its competitors. This is 69% above median its historical median of 9.85. According to the industry distribution chart, Gland Pharma ranks #296 out of 809 companies in the Drug Manufacturers industry, placing it in the top 36.6%.
Is Gland Pharma's 3-Year EBITDA Growth Rate too high?
Gland Pharma's current 3-Year EBITDA Growth Rate of 16.60% is 69% above median its 10-year median of 9.85. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Gland Pharma's value of 16.60% is 86.5% above this industry median. Based on the distribution chart, Gland Pharma ranks #296 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gland Pharma has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #296 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Gland Pharma in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Gland Pharma's value of 16.60% is 86.5% above this benchmark. While the company's 10-year median is 9.85 vs. the industry median of 8.90, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current 3-Year EBITDA Growth Rate of 16.60% is 86.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gland Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current 3-Year EBITDA Growth Rate is 16.60%, which is 69% above median its own 10-year median of 9.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2,239.48, compared to a current price of ₹2,970.20 — trading 32.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.60%, which is 69% above median its 10-year median of 9.85 and 86.5% above the Drug Manufacturers industry median of 8.90. Gland Pharma's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current 3-Year EBITDA Growth Rate is 16.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,970.20 is trading 32.6% above its estimated GF Value™ of ₹2,239.48.
GuruFocus considers Gland Pharma to be Significantly Overvalued.
Key valuation signals for NSE:GLAND:
3-Year EBITDA Growth Rate: 16.60% (69% above median its 10-year median of 9.85)
GF Value™: ₹2,239.48 vs. price of ₹2,970.20 (32.6% above fair value)
Industry Position: 86.5% above the Drug Manufacturers median (#296 of 809)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
81GF Score
Get the complete analysis for NSE:GLAND
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
